Cargando…

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan

Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly diagnosed, transplant-ineli...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Jeng-Shiun, Kuo, Yi-Chun, Shi, Hon-Yi, Wang, Ming-Chung, Wang, Li-Ying, Chuang, Tzer-Ming, Ke, Ya-Lun, Yeh, Tsung-Jang, Gau, Yu-Ching, Wang, Hui-Ching, Cho, Shih-Feng, Hsiao, Samuel Yien, Liu, Yi-Chang, Hsu, Chin-Mu, Hsiao, Hui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880219/
https://www.ncbi.nlm.nih.gov/pubmed/35207619
http://dx.doi.org/10.3390/jpm12020130
_version_ 1784659132645638144
author Du, Jeng-Shiun
Kuo, Yi-Chun
Shi, Hon-Yi
Wang, Ming-Chung
Wang, Li-Ying
Chuang, Tzer-Ming
Ke, Ya-Lun
Yeh, Tsung-Jang
Gau, Yu-Ching
Wang, Hui-Ching
Cho, Shih-Feng
Hsiao, Samuel Yien
Liu, Yi-Chang
Hsu, Chin-Mu
Hsiao, Hui-Hua
author_facet Du, Jeng-Shiun
Kuo, Yi-Chun
Shi, Hon-Yi
Wang, Ming-Chung
Wang, Li-Ying
Chuang, Tzer-Ming
Ke, Ya-Lun
Yeh, Tsung-Jang
Gau, Yu-Ching
Wang, Hui-Ching
Cho, Shih-Feng
Hsiao, Samuel Yien
Liu, Yi-Chang
Hsu, Chin-Mu
Hsiao, Hui-Hua
author_sort Du, Jeng-Shiun
collection PubMed
description Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly diagnosed, transplant-ineligible myeloma patients with VTD or VMP therapy were enrolled from two medical centers in southern Taiwan. Quality-adjusted life years (QALYs) were used as the measurement unit of the effectiveness evaluation, and the incremental cost-effectiveness ratio (ICER) was used for comparison between the two groups. A net monetary benefit approach and cost-effectiveness acceptability curve were also used for the cost-effectiveness assessment. A one-way sensitivity analysis was used to check the impact of different parameters. In total, 77 patients were enrolled in the study with 43 patients in the VTD group and 34 patients in the VMP group. Clinical presentations were similar without significant difference, except the VTD group had a higher survival rate (p = 0.029). Comparisons of the two groups over an eight-month time horizon revealed a significant lower mean of direct medical costs in the VTD group than in the VMP group (p < 0.001), and a significantly higher average QALY was gained (p < 0.001). Conclusions: The study demonstrated the greater clinical benefit and cost-effectiveness of VTD compared to VMP therapy in transplant-ineligible, newly diagnosed myeloma patients.
format Online
Article
Text
id pubmed-8880219
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88802192022-02-26 The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan Du, Jeng-Shiun Kuo, Yi-Chun Shi, Hon-Yi Wang, Ming-Chung Wang, Li-Ying Chuang, Tzer-Ming Ke, Ya-Lun Yeh, Tsung-Jang Gau, Yu-Ching Wang, Hui-Ching Cho, Shih-Feng Hsiao, Samuel Yien Liu, Yi-Chang Hsu, Chin-Mu Hsiao, Hui-Hua J Pers Med Article Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly diagnosed, transplant-ineligible myeloma patients with VTD or VMP therapy were enrolled from two medical centers in southern Taiwan. Quality-adjusted life years (QALYs) were used as the measurement unit of the effectiveness evaluation, and the incremental cost-effectiveness ratio (ICER) was used for comparison between the two groups. A net monetary benefit approach and cost-effectiveness acceptability curve were also used for the cost-effectiveness assessment. A one-way sensitivity analysis was used to check the impact of different parameters. In total, 77 patients were enrolled in the study with 43 patients in the VTD group and 34 patients in the VMP group. Clinical presentations were similar without significant difference, except the VTD group had a higher survival rate (p = 0.029). Comparisons of the two groups over an eight-month time horizon revealed a significant lower mean of direct medical costs in the VTD group than in the VMP group (p < 0.001), and a significantly higher average QALY was gained (p < 0.001). Conclusions: The study demonstrated the greater clinical benefit and cost-effectiveness of VTD compared to VMP therapy in transplant-ineligible, newly diagnosed myeloma patients. MDPI 2022-01-19 /pmc/articles/PMC8880219/ /pubmed/35207619 http://dx.doi.org/10.3390/jpm12020130 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Du, Jeng-Shiun
Kuo, Yi-Chun
Shi, Hon-Yi
Wang, Ming-Chung
Wang, Li-Ying
Chuang, Tzer-Ming
Ke, Ya-Lun
Yeh, Tsung-Jang
Gau, Yu-Ching
Wang, Hui-Ching
Cho, Shih-Feng
Hsiao, Samuel Yien
Liu, Yi-Chang
Hsu, Chin-Mu
Hsiao, Hui-Hua
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title_full The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title_fullStr The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title_full_unstemmed The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title_short The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
title_sort cost-effectiveness analysis of transplant-ineligible myeloma patients with bortezomib plus thalidomide plus dexamethasone (vtd) or bortezomib plus melphalan plus prednisolone (vmp) treatment in southern taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880219/
https://www.ncbi.nlm.nih.gov/pubmed/35207619
http://dx.doi.org/10.3390/jpm12020130
work_keys_str_mv AT dujengshiun thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT kuoyichun thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT shihonyi thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wangmingchung thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wangliying thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT chuangtzerming thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT keyalun thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT yehtsungjang thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT gauyuching thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wanghuiching thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT choshihfeng thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsiaosamuelyien thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT liuyichang thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsuchinmu thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsiaohuihua thecosteffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT dujengshiun costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT kuoyichun costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT shihonyi costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wangmingchung costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wangliying costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT chuangtzerming costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT keyalun costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT yehtsungjang costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT gauyuching costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT wanghuiching costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT choshihfeng costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsiaosamuelyien costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT liuyichang costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsuchinmu costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan
AT hsiaohuihua costeffectivenessanalysisoftransplantineligiblemyelomapatientswithbortezomibplusthalidomideplusdexamethasonevtdorbortezomibplusmelphalanplusprednisolonevmptreatmentinsoutherntaiwan